Dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) is a
serine/threonine kinase that belongs to the DYRK family of proteins, a subgroup of the …

Alternative splicing (AS) serves as a pivotal mechanism in transcriptional regulation,
engendering transcript diversity, and modifications in protein structure and functionality …

The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …

In lung adenocarcinoma (LUAD), loss-of-function mutations in the splicing factor RBM10
frequently co-occur with oncogenic EGFR mutations. A detailed understanding of the …

RNA-binding motif protein 10 (RBM10) is a frequently mutated tumor suppressor in lung
adenocarcinoma (LUAD). Yet, it remains unknown whether cancer-derived mutant RBM10 …

Mutations in splicing factor (SF) genes SRSF2, U2AF1, SF3B1, and ZRSR2 are now
considered adverse risk in the European LeukemiaNet 2022 acute myeloid leukemia (AML) …

RNA splicing is a key regulatory step in the proper control of gene expression. It is a highly
dynamic process orchestrated by the spliceosome, a macro-molecular machinery that …

Molecularly defined secondary acute myeloid leukemia is associated with a prior myeloid
neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined …

Nuclear factor erythroid 2-related factor 2 (NRF2) hyperactivation has been established as
an oncogenic driver in a variety of human cancers, including non-small cell lung cancer …

Acute leukemia is characterized by clonal heterogeneity that contributes to poor drug
responses in patients. Despite treatment advances, the occurrence of relapse remains a …